articleThe Lancet OncologySep 26, 2017Closed access

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

AVArjun Vasant BalarDCDaniel CastellanoPHPeter H. O’DonnellPGPetros GrivasJVJacqueline Vuky

NYU Langone Health · Hospital Universitario 12 De Octubre · +10 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,338
total citations
FWCI
128.65
Percentile
100%
References
25
Citations per year

Authors

15

Topics & keywords

Topics
Keywords
  • Medicine
  • Pembrolizumab
  • Clinical endpoint
  • Internal medicine
  • Response Evaluation Criteria in Solid Tumors
  • Oncology
  • Metastatic Urothelial Carcinoma
  • Phases of clinical research
No related works found for this paper.

Funding